A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 101–200 of 1,138
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 114
Self-citationBile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Fiorucci, S., Biagioli, M., Sepe, V., Zampella, A., & Distrutti, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1763302 · Cited by 104
Cariello, M., Piccinin, E., García‐Irigoyen, O., Sabbà, C., & Moschetta, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.019 · Cited by 112
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99
Innate Immunity and Pathogenesis of Biliary Atresia
Ortiz‐Perez, A., Donnelly, B., Temple, H., Tiao, G. M., Bansal, R., & Mohanty, S. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00329 · Cited by 112
“In the future, the agents which are currently being tested in cholestatic and fibrotic liver diseases in adults (132) can also be investigated in BA, such as the farnesoid X receptor (FXR) agonist, obeticholic acid, and the modified bile acid norursodeoxycholic acid, which are also currently used in primary biliary ch…”
BackgroundDysregulation of glutathione synthesis in liver disease
Lu, S. C.-L. (2020) · Liver Research · doi:10.1016/j.livres.2020.05.003 · Cited by 98
Al-Dury, S., & Marschall, H.-U. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00931 · Cited by 95
“…lipoprotein (HDL) cholesterol probably due to decreased apolipoprotein (apo) A1 and increased scavenger receptor-B1 (SR-B1) expression, are observed by the administration of FXR activators such as obeticholic acid, which is a semisynthetic BA derivative (Nevens et al., 2016; Pencek et al., 2016).”
BackgroundSelf-citationCorpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000529 · Cited by 94
Self-citationYounossi, Z. M., Stepanova, M., Nader, F., Loomba, R., Anstee, Q. M., Ratziu, V., Harrison, S., Sanyal, A. J., Schattenberg, J. M., Barritt, A. S., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.020 · Cited by 93
A Current Understanding of Bile Acids in Chronic Liver Disease
Farooqui, N., Elhence, A., & Shalimar, S. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.08.017 · Cited by 100
Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer
Liu, T., Yang, H., Fan, W., Tu, J., Li, T. W. H., Wang, J., Shen, H., Yang, J., Xiong, T., Steggerda, J. A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.032 · Cited by 91
Kremer, A. E., Mayo, M. J., Hirschfield, G., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A., McWherter, C. A., & Choi, Y. (2022) · Liver International · doi:10.1111/liv.15039 · Cited by 89
“Pruritus VAS (0100) VAS ≥40 VAS <40 23 [24] 59 [15] 11 [11] 30 [28] 65 [17] 13 [14]”
Self-citationManagement of cholestatic disease in 2017
de Vries, E., & Beuers, U. (2017) · Liver International · doi:10.1111/liv.13306 · Cited by 90
Self-citationMcIlvride, S., Dixon, P. H., & Williamson, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.05.003 · Cited by 113
“For example, the bile acid analogue obeticholic acid (OCA) is a potential new therapy for primary biliary cholangitis (PBC; Nevens et al., 2016) and primary sclerosing cholangitis (PSC; Clinical trials identifier: NCT02177136), among other metabolic diseases.”
BackgroundSamur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology · doi:10.1002/hep.28932 · Cited by 89
“It was also the most experienced side effect in POISE.((11)) PBC patients in our model had pruritus during the first year of treatment, which varied in severity and was classified as mild, moderate, or severe (Supporting Table S3).”
BackgroundMethodInfluentialHegade, V. S., Mells, G. F., Fisher, H., Kendrick, S., DiBello, J., Gilchrist, K., Alexander, G. J., Hirschfield, G. M., Sandford, R. N., & Jones, D. E. J. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.007 · Cited by 88
Self-citationGoto, T., Itoh, M., Suganami, T., Kanai, S., Shirakawa, I., Sakai, T., Asakawa, M., Yoneyama, T., Kai, T., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26383-8 · Cited by 88
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
Corpechot, C., Chazouillères, O., Belnou, P., Montano-Loza, A. J., Mason, A., Ebadi, M., Eurich, D., Chopra, S., Jacob, D., Schramm, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.043 · Cited by 87
Self-citationFXR modulators for enterohepatic and metabolic diseases
Wang, H., He, Q., Wang, G., Xu, X., & Hao, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1527906 · Cited by 87
“However, results from a recent clinical trial showed that changes in noninvasive measures of liver fibrosis did not differ significantly between OCA and placebo treatment [107].”
BackgroundResultInfluentialKriegermeier, A. A., & Green, R. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00149 · Cited by 97
Pregnancy and bile acid disorders
Pataia, V., Dixon, P. H., & Williamson, C. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00028.2017 · Cited by 99
Kim, D. J., Yoon, S., Ji, S. C., Yang, J., Kim, Y., Lee, S., Yu, K., Jang, I., Chung, J., & Cho, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-30349-1 · Cited by 107
Al-Dury, S., Wahlström, A., Wahlin, S., Langedijk, J., Elferink, R. O., Ståhlman, M., & Marschall, H.-U. (2018) · Scientific Reports · doi:10.1038/s41598-018-25214-0 · Cited by 85
Self-citationReal-world experience with obeticholic acid in patients with primary biliary cholangitis
D’Amato, D., De Vincentis, A., Malinverno, F., Viganò, M., Alvaro, D., Pompili, M., Picciotto, A., Palitti, V. P., Russello, M., Storato, S., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100248 · Cited by 85
“The population enrolledwas similar to that described in the Poise trial(5) with the following exceptions: (1) 61 patients (32%) in our cohort had cirrhosis (clinically and/or histologically), compared with an estimated 20% in the Poise trial based on transient elastography, which was, however, performed only in 43% of…”
MethodResultInfluentialSelf-citationWang, R., Li, B., Huang, B., Li, Y., Liu, Q., Lyu, Z., Chen, R., Qian, Q., Liang, X. S., Pu, X., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.014 · Cited by 98
Cholestatic liver diseases: new targets, new therapies
Santiago, P., Scheinberg, A. R., & Levy, C. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818787400 · Cited by 86
S2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr. 021-27
Authors, Collaborators:, durch:, E. B., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (. (., (DGIM), D. G. F. I. M., (DCCV), D. M. C. U. V., e.V., D. L., (DEGUM), D. G. F. U. I. D. M., (DGE-BV), D. G. F. E. U. B. V., (DGKJ), D. G. F. K. U. J., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-120199 · Cited by 90
Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
Kjærgaard, K., Frisch, K., Sørensen, M., Munk, O. L., Hofmann, A. F., Horsager, J., Schacht, A. C., Erickson, M., Shapiro, D., & Keiding, S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.028 · Cited by 81
Self-citationBowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.033 · Cited by 80
Self-citationRecent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
“Ursodeoxycholic acid is the first-line therapy in PBC and all novel therapies are primarily intended as add-on therapy to UDCA [10].”
BackgroundInfluentialSelf-citationThe functions of gut microbiota-mediated bile acid metabolism in intestinal immunity
He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 124
“However, long-term trials revealed notable side effects such as pruritus, dyslipidemia, and even hepatotoxicity at higher doses [256–258].”
The interrelationship between bile acid and vitamin A homeostasis
Saeed, A., Hoekstra, M., Hoeke, M. O., Heegsma, J., & Faber, K. N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.01.007 · Cited by 96
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 90
Vesterhus, M., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80
Developments in bile salt based therapies: A critical overview
Donkers, J. M., Abbing, R. L. P. R., & van de Graaf, S. F. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.018 · Cited by 80
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Invernizzi, P., Carbone, M., Jones, D., Levy, C., Little, N., Wiesel, P., Nevens, F., & the study investigators (2023) · Liver International · doi:10.1111/liv.15596 · Cited by 79
Self-citationVuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
Novel perspectives in the management of decompensated cirrhosis
Bernardi, M., & Caraceni, P. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0045-2 · Cited by 90
Sanyal, A. J., Ling, L., Beuers, U., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Hirschfield, G. M. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100255 · Cited by 79
Self-citationSoret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16336 · Cited by 78
“ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (10), pp.”
Self-citationObeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders
Fiorucci, S., Giorgio, C. D., & Distrutti, E. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_227 · Cited by 86
Mayo, M. J., Carey, E., Smith, H. T., Mospan, A. R., McLaughlin, M., Thompson, A., Morris, H. L., Sandefur, R., Kim, W. R., Bowlus, C., et al. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07581-x · Cited by 78
“Recent large clinical trials have found a baseline prevalence of pruritus in patients with PBC of about 50–70% [1, 2].”
BackgroundSelf-citationJung, K., Kim, M., So, J., Lee, S., Ko, S., & Shin, D. (2021) · Hepatology · doi:10.1002/hep.31679 · Cited by 77
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 92
An update on the recent advances in antifibrotic therapy
Tacke, F., & Weiskirchen, R. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1530110 · Cited by 76
“For instance, obeticholic acid has been the first drug in decades to become licensed as a second-line therapy in primary biliary cholangitis [37], and cenicriviroc is also being tested in primary sclerosing cholangitis [67].”
BackgroundBadman, M. K., Chen, J., Desai, S., Vaidya, S., Neelakantham, S., Zhang, J., Gan, L., Danis, K., Laffitte, B., & Klickstein, L. B. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.762 · Cited by 75
FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis
Panzitt, K., Jungwirth, E., Krones, E., Lee, J. M., Pollheimer, M., Thallinger, G. G., Kolb-Lenz, D., Xiao, R., Thorell, A., Trauner, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.014 · Cited by 75
Self-citationPPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleo, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 75
Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A., Newton, J. L., & Jones, D. E. (2019) · Hepatology · doi:10.1002/hep.30099 · Cited by 75
“(2-4) Fatigue, the symptom most frequently reported by PBC patients,(2-4) can occur at any point in the disease course, and its severity is unrelated to liver disease activity or degree of liver damage and is not improved by current first or second line therapy.(5-7) Given its impact and lack of response to therapy, i…”
BackgroundSelf-citationBile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Primary biliary cholangitis: Old and novel therapy
Floreani, A., & Mangini, C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.06.020 · Cited by 82
Self-citationHameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14492 · Cited by 73
“Weight loss with OCA therapy has not been reported in treatment studies of patients with primary biliary cholangitis.(19) The mechanism underlying this weight loss in patients with NASH is unknown but FXR TABLE 2 (Continued)”
BackgroundResultDay, J., Patel, P., Parkes, J., & Rosenberg, W. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027359 · Cited by 73
Novel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 77
“Other important defence mechanisms include (1) the bicarbonate umbrella, (2) cholehepatic shunting, and (3) antiinflammatory signalling.”
BackgroundInfluentialDrug Therapies for Chronic Cholestatic Liver Diseases
Wagner, M., & Fickert, P. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021059 · Cited by 78
Dongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 77
Kowdley, K. V., Hirschfield, G. M., Coombs, C., Malecha, E. S., Bessonova, L., Li, J., Rathnayaka, N. S., Mells, G. F., Jones, D. E., Trivedi, P. J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003029 · Cited by 80
Self-citationSynthetic Approaches to New Drugs Approved During 2016
Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 72
Immunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Yang, J., Tang, X., Zhu, L., Chen, M., & Sun, L. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0327 · Cited by 73
Review: Pathogenesis of cholestatic liver diseases
Yokoda, R. T., & Rodríguez, E. A. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.423 · Cited by 81
Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Zampella, A., Monti, M. C., Scarpelli, P. T., Ricci, P., Distrutti, E., & Fiorucci, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.07.006 · Cited by 72
Review article: therapeutic bile acids and the risks for hepatotoxicity
Ashby, K., Almario, E. N., Tong, W., Borlak, J. T., Mehta, R., & Chen, M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14678 · Cited by 70
“67x ULN); no effect was demonstrated on total bilirubin, as 93% of patients had normal total bilirubin at enrolment and total bilirubin is not expected to worsen in patients who have early stage disease, in a 1-year trial.(47) Recently, another synthetic bile acid, norursodeoxycholic acid, concluded a phase II clinica…”
BackgroundBile acid receptors and the kidney
Herman‐Edelstein, M., Weinstein, T., & Levi, M. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000374 · Cited by 75
Nakada, E. M., Bhakta, N. R., Korwin-Mihavics, B. R., Kumar, A., Chamberlain, N., Bruno, S. R., Chapman, D. G., Hoffman, S. M., Daphtary, N., Aliyeva, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.98101 · Cited by 73
Papazyan, R., Liu, X., Liu, J., Dong, B., Plummer, E. M., Lewis, R. D., Roth, J. D., & Young, M. A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081935 · Cited by 67
“in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA (16).”
BackgroundBile acids and cardiovascular function in cirrhosis
Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 72
“…optimistic improve - ment in composite endpoints was noted in two randomized, double-blind, placebo-controlled trials after 12 months of treatment 97,98 which has led to the accelerated FDA approval of OCA for treatment of PBC. 99 Studies are also underway in primary sclerosing cholangitis,…”
BackgroundThompson, M. D., Moghe, A., Cornuet, P., Marino, R., Tian, J., Wang, P., Ma, X., Abrams, M., Locker, J., Monga, S. P., et al. (2018) · Hepatology · doi:10.1002/hep.29371 · Cited by 66
“Indeed, a phase 3 clinical trial has demonstrated that the FXR agonist obeticholic acid, either alone or in combination with ursodeoxycholic acid, leads to a significant reduction in serum markers of liver injury and cholestasis in patients with primary biliary cholangitis.((40)) However, this favorable outcome was as…”
BackgroundYu, L., Liu, Y., Wang, S., Zhang, Q., Zhao, J., Zhang, H., Narbad, A., Tian, F., Zhai, Q., & Chen, W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181930 · Cited by 76
“Therefore, another drug, obeticholic acid (OCA), is used in patients who are unresponsive or intolerant to UDCA; however, only 50% of patients are responsive.(6,7) Those who do not respond to UDCA and/or OCA medication are in danger of progressing to biliary cirrhosis, end-stage liver disease, or even death.”
BackgroundThe Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
Hov, J., & Karlsen, T. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608801 · Cited by 65
Gracia‐Sancho, J., Manicardi, N., Ortega‐Ribera, M., Maeso‐Díaz, R., Guixé‐Muntet, S., Fernández‐Iglesias, A., Hide, D., García‐Calderó, H., Boyer‐Díaz, Z., Contreras, P. C., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1360 · Cited by 64
“(11) Unfortunately, current options to improve ACLD and its main clinical complications are limited,(3,11) and although statins have shown beneficial effects on portal hypertension and survival, the risk reduction afforded by these and other agents is limited,(12,13) indicating that new therapeutic strategies are warr…”
BackgroundStructure-guided discovery of bile acid derivatives for treating liver diseases without causing itch
Yang, J. J. J., Zhao, T., Fan, J., Zou, H., Lan, G., Guo, F., Shi, Y., Ke, H., Yu, H., Yue, Z., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.001 · Cited by 80
Dvořák, Z., Sokol, H., & Mani, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.013 · Cited by 66
“Several clinical trials were carried out with highly potent FXR synthetic agonist obeticholic acid, including those against type II diabetes and NAFLD (31), non-cirrhotic nonalcoholic steatohepatitis (32), primary sclerosing cholangitis (33) and primary biliary cholangitis (34).”
BackgroundFan, J., Tang, X., Wang, Q., Zhang, Z., Wu, S., Li, W., Liu, S., Yao, G., Chen, H., & Sun, L. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0979-x · Cited by 65
Gerussi, A., Bernasconi, D. P., O'Donnell, S. E., Lammers, W. J., Van Buuren, H., Hirschfield, G., Janssen, H., Corpechot, C., Reig, A., Pares, A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.006 · Cited by 62
Self-citationFarnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
Ceulemans, L. J., Verbeke, L., Decuypere, J.-P., Farré, R., De Hertogh, G., Lenaerts, K., Jochmans, I., Monbaliu, D., Nevens, F., Tack, J., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169331 · Cited by 62
Self-citationObeticholic acid may increase the risk of gallstone formation in susceptible patients
Al-Dury, S., Wahlström, A., Panzitt, K., Thorell, A., Ståhlman, M., Trauner, M., Fickert, P., Bäckhed, F., Fändriks, L., Wagner, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.011 · Cited by 62
Self-citationSeladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Kremer, A. E., Mayo, M. J., Hirschfield, G. M., Levy, C., Bowlus, C. L., Jones, D. E., Johnson, J. D., McWherter, C. A., & Choi, Y.-J. (2024) · Hepatology · doi:10.1097/hep.0000000000000728 · Cited by 61
“Of importance, FXR agonists, which are known to improve cholestatic markers (eg., ALP) while causing or worsening pruritus in patients with PBC, [30] dose-dependently increased serum IL-31 in clinical studies in NASH, PBC, and primary sclerosing cholangitis, and in mice with humanized livers.”
BackgroundSelf-citationMarschall, H.-U., Henriksson, I., Lindberg, S., Söderdahl, F., Thuresson, M., Wahlin, S., & Ludvigsson, J. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-47890-2 · Cited by 60
Self-citationLemoinne, S., & Friedman, S. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.006 · Cited by 60
The pathogenesis, models and therapeutic advances of primary biliary cholangitis
Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111754 · Cited by 64
Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
Rodrigues, P. M., Perugorria, M. J., Santos-Laso, A., Bujanda, L., Beuers, U., & Banales, J. M. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.020 · Cited by 57
Self-citationXu, J., Wang, Y., Khoshdeli, M., Peach, M., Chuang, J.-C., Lin, J. H., Tsai, W., Mahadevan, S., Minto, W. C., Diehl, L. J., et al. (2022) · Hepatology · doi:10.1002/hep.32599 · Cited by 66
“Pruritus, a poorly understood and debilitating feature of cholestatic liver disease, is also commonly associated with treatment with OCA[2,3,15] and other nonsteroidal FXR agonists.”
BackgroundResultSelf-citationAssessment of fatigue and its impact in chronic liver disease
Younossi, Z. M., Kremer, A. E., Swain, M. G., Jones, D. E., Bowlus, C. L., Trauner, M., Henry, L. L., & Gerber, L. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.008 · Cited by 63
Self-citationReal‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1518 · Cited by 58
Self-citationPark, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 67
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology · doi:10.1002/hep.32011 · Cited by 45
“First- line therapy for all patients is with ursodeoxycholic acid (UDCA),(9) with second- line agents, such as obeticholic acid (OCA) and bezafibrate, being introduced in patients showing an inadequate response to UDCA.”
BackgroundInfluentialSelf-citationGaloosian, A., Hanlon, C. L., Zhang, J., Holt, E. W., & Yimam, K. K. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00049 · Cited by 76
“Up to 56% of patients in the 5–10 mg titration group and 68% of patients in the 10 mg group discontinued OCA compared to 38% in the placebo arm.(73,74) Pruritus returned back to baseline during the open-lab extension phase of the study.”
BackgroundResultBidault, V., Merlen, G., Glénisson, M., Doignon, I., Garcin, I., Pean, N., Boisgard, R., Bedoya, J. U., Sérino, M., Ullmer, C., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100214 · Cited by 61
“This is particularly true in the field of metabolic diseases such as obesity and diabetes,(17) as well as for cholestatic liver diseases.(27) However, in the liver repair field, BAcentred therapeutic strategies are still underexplored, awaiting for experimental substratum.”
BackgroundPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 80
Self-citationFibrotic Events in the Progression of Cholestatic Liver Disease
Wu, H., Chen, C., Ziani, S., Nelson, L. J., Avila, M. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Cells · doi:10.3390/cells10051107 · Cited by 65
“Currently, there is no drug therapy for PSC [5,198].”
BackgroundInfluentialVincenzo, F. D., Puca, P., Lopetuso, L. R., Petito, V., Masi, L., Bartocci, B., Murgiano, M., Felice, M. D., Petronio, L., Gasbarrini, A., et al. (2022) · Nutrients · doi:10.3390/nu14132664 · Cited by 64
Bone Health in Patients With Liver Diseases
Danford, C. J., Trivedi, H. D., & Bonder, A. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.01.004 · Cited by 70
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Mayo, M. J. (2022) · Hepatology · doi:10.1002/hep.32405 · Cited by 63
“This combination biochemical endpoint was achieved in 46% of OCA- treated subjects versus 10% of placebo subjects The main side effect seen was pruritus, which was noted in 56% of OCA- treated subject versus 38% of placebo- treated subjects.[66] The benefit and safety of OCA are not yet established in patients with de…”
BackgroundOsteoporosis in primary biliary cholangitis
Danford, C. J., Trivedi, H. D., Papamichael, K., Tapper, E. B., & Bonder, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3513 · Cited by 56
An, P., Wei, G., Huang, P., Li, W., Qi, X., Lin, Y., Vaid, K. A., Wang, J., Zhang, S., Li, Y., et al. (2020) · Liver International · doi:10.1111/liv.14490 · Cited by 62
Garcia, M., Thirouard, L., Sèdes, L., Monrose, M., Holota, H., Caira, F., Volle, D. H., & Beaudoin, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113630 · Cited by 62
“Therefore, it has come as no surprise that the high affinity 6-ECDCA FXRα ligand was able to restore reduced bile flow and improve cholestasis in several preclinical animal models of cholestasis [102,123], as well as in patients with PBC [124].”
BackgroundBowlus, C. L., Yang, G.-X., Liu, C. H., Johnson, C. R., Dhaliwal, S. S., Frank, D., Levy, C., Peters, M. G., Vierling, J. M., & Gershwin, M. E. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.005 · Cited by 56
Self-citationTabibian, J. H., Ali, A. H., & Lindor, K. D. (2018) · Europe PMC (PubMed Central) · Cited by 63
Self-citation
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.